Partnerships

Past and existing partnerships

Areas of collaboration 

Superbranche, open to innovation in imaging and advanced therapies

A key player in the development of new-generation tracers, Superbranche is committed to advancing medical imaging technologies to meet the challenges of tomorrow's medicine.
Our expertise in nanotechnology applied to MRI and MPI (Magnetic Particle Imaging) positions us as a strategic partner for academic research platforms, bioproducers of advanced therapy drugs (ATDs), biotechnology companies and the pharmaceutical industry.

We are particularly open to collaborations in the following areas:

  • Preclinical validation of innovative therapy strategies (by cells or vesicles): we offer tools to evaluate tropism towards sites of interest, biodistribution by quantitative imaging and the functionality of therapeutic cells before their passage into clinical trials
  • In vitro labeling and real-time in vivo tracking by magnetic imaging applied to stem cells, induced pluripotent cells (iPSCs) or extracellular vesicles (exosomes).
  • The co-development of integrated solutions for precision medicine, combining diagnosis, functional imaging, and therapeutic targeting.

Our technological platform and our openness to co-innovation make Superbranche an agile partner committed to biomedical progress.

Cell viability on human mesenchymal stromal cells from 3 donors (hASC1, hASC2 and hASC3) after 0, 1 and 7 days post-internalization of SUPERSPIO20. Credit: Claire Abeza, ECELL France Montpellier Research Platform
Cell viability on human mesenchymal stromal cells from 3 donors (hASC1, hASC2 and hASC3) after 0, 1 and 7 days post-internalization of SUPERSPIO20. Credit: Claire Abeza, ECELL France Montpellier Research Platform
hMSCs marked by SUPERSPIO. Credit: JWM Bulte, JHU
hMSCs marked by SUPERSPIO. Credit: JWM Bulte, JHU

Johns Hopkins University

As a long-standing partner of Superbranche, our close collaboration in the field of cellular imaging has demonstrated the superior sensitivity of our SUPERSPIO technology compared to currently marketed tracers, with several studies conducted on iPSC-derived EVs and iPSC-derived NPCs, or a performance of SUPERSPIO20 approximately 20% higher than that of the reference product.

These results highlight the unique potential of SUPERSPIO in regenerative medicine and in vivo cell tracking approaches.

Partners Regulation Finance and Administration

Academic partners

Strategic partners

Funding partners

Contact us

Would you like to know more or start a collaboration?
Do not hesitate to write to us, our team will be happy to respond to you as soon as possible.

Contact us
Get a quote